The Curis Lifesciences IPO is one of the notable SME issues lined up on NSE SME this November. If you are an investor looking at pharmaceutical companies with steady growth, consistent profitability, and expanding global reach, this IPO may be worth following closely.
The issue opens for subscription on November 7, 2025, and closes on November 11, 2025, with a book-built structure and a total fundraising target of around ₹27.52 crores.
This guide breaks down all key details in a simple, conversational Indian English tone so that readers can easily understand dates, price band, financial highlights, and whether this IPO fits into a long-term portfolio.
Contents
Curis Lifesciences IPO Key Highlights
| IPO Detail | Information |
|---|---|
| IPO Open Date | November 7, 2025 |
| IPO Close Date | November 11, 2025 |
| Face Value | ₹10 per share |
| IPO Price Band | ₹120 to ₹128 per share |
| Issue Size | Approx ₹27.52 crores |
| Fresh Issue | Approx ₹27.52 crores |
| Issue Type | Book Built Issue |
| IPO Listing | NSE SME |
| DRHP Draft Prospectus | View PDF |
| RHP Draft Prospectus | View PDF |
Above are the most important details investors look for dates, price band, and listing information. The allotment result will be declared on November 12, 2025, and listing will take place on November 14, 2025, on NSE SME.
Since this is a fresh issue, all funds raised will remain with the company for its expansion and operational needs.
Curis Lifesciences IPO
Open: 7-11 Nov 2025
Issue Size: ₹27.52 Cr.
Objective: Upgrade their plants, build storage, clear debt, and for working capital.
Exchange: NSE SME
Curis Lifesciences IPO Detailed Timeline
| Event | Date |
|---|---|
| IPO Open Date | November 7, 2025 |
| IPO Close Date | November 11, 2025 |
| Basis of Allotment | November 12, 2025 |
| Refunds | November 13, 2025 |
| Credit to Demat | November 13, 2025 |
| IPO Listing Date | November 14, 2025 |
| Bidding Cut-off | November 11, 2025 at 5 PM |
Curis Lifesciences IPO Market Lot
Investors must apply in lots of 2,000 shares. This makes the entry amount on the higher side for an SME IPO, which is common in such offerings.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 | 2,000 | ₹2,56,000 |
| Retail Maximum | 2 | 2,000 | ₹2,56,000 |
| S-HNI Minimum | 3 | 3,000 | ₹3,84,000 |
| S-HNI Maximum | 7 | 7,000 | ₹8,96,000 |
| B-HNI Minimum | 8 | 8,000 | ₹10,24,000 |
The fixed lot structure ensures equal participation opportunities within each investor category.
Curis Lifesciences IPO Reservation Breakdown
| Investor Category | Shares Offered | % Share |
|---|---|---|
| Anchor Investor | 6,09,000 shares | 28.33% |
| QIB (Ex Anchor) | 4,09,000 shares | 19.02% |
| NII | 3,08,000 shares | 14.33% |
| Retail | 7,16,000 shares | 33.30% |
The IPO follows a balanced allocation pattern suitable for both institutional and retail investors. Retail investors get a 35 percent allocation, which is reasonable compared to several SME issues that allocate less to retail.
- Also Read:
- Pine Labs IPO
Anchor Investors
| Anchor Detail | Information |
|---|---|
| Anchor Bidding Date | November 6, 2025 |
| Anchor Investors List | View PDF |
| Shares Offered | 6,09,000 shares |
| Anchor Size | ₹7.80 crores |
| Lock-in (50% for 30 Days) | December 12, 2025 |
| Lock-in (50% for 90 Days) | February 10, 2026 |
Anchor investment strengthens confidence and can influence initial response. The anchor book will open a day before the IPO.
About Curis Lifesciences Limited
Curis Lifesciences Limited, established in 2010, operates in the pharmaceutical manufacturing and distribution sector. Over the past decade, the company has built a portfolio that covers Tablets, Capsules, External Preparations, Oral Liquids, and Sterile Ophthalmic Ointments.
A unique aspect is that the company works under multiple models:
• Contract manufacturing
• License manufacturing
• Manufacturing under its own brand
• Distribution of ready-made pharma products to wholesalers
The company serves more than 100 corporate clients across India and also has international presence. It supplies its own branded products in markets such as Yemen and Kenya. This shows the company’s early but promising entry into global pharmaceutical markets.
Curis Lifesciences owns a modern factory in Sanand, Gujarat, known for its regulatory compliance and strict quality processes. As of July 31, 2025, the company had 95 permanent employees.
Business Strengths
• Wide product range across dosage forms
• Contract manufacturing for leading Indian and foreign pharma clients
• Consistent revenue and profit growth in the last three years
• Expanding international presence
• Modern manufacturing facility in Gujarat
• Low attrition rate and stable workforce
These factors help build a steady revenue pipeline and recurring business.
Curis Lifesciences IPO Financial Performance
| Period Ended | Revenue | Expense | PAT | Assets |
|---|---|---|---|---|
| 2023 | ₹36.42 cr | ₹34.23 cr | ₹1.88 cr | ₹29.75 cr |
| 2024 | ₹35.87 cr | ₹28.70 cr | ₹4.87 cr | ₹33.88 cr |
| 2025 | ₹49.65 cr | ₹41.38 cr | ₹6.11 cr | ₹42.53 cr |
| July 2025 | ₹19.51 cr | ₹15.79 cr | ₹2.87 cr | ₹56.29 cr |
The company has shown solid financial progress over the last three years. Above is a clear summary:
The numbers reflect:
• Revenue improving significantly
• Profit increasing year-on-year
• Better control over expenses
• Assets strengthening
The FY2025 revenue jump from ₹35.87 crores to ₹49.65 crores indicates momentum in client demand and stronger distribution channels.
Valuation Metrics (FY2025)
| KPI | Value |
|---|---|
| ROE | 55.25% |
| ROCE | 27.83% |
| EBITDA Margin | 19.41% |
| PAT Margin | 12.43% |
| Debt-to-equity | 0.96 |
| EPS (Basic) | ₹10.29 |
| P/E Ratio | Not applicable |
| RoNW | 37.62% |
| NAV | ₹27.34 |
These valuation parameters help investors assess whether the company is fairly priced. The company posts strong margins and returns on equity, which are higher than several SME pharma peers.
Peer Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
|---|---|---|---|---|---|
| Sotac Pharmaceuticals Ltd. | 4.32 | 18.30 | 9.00% | 47.99 | ₹64.76 cr |
| Lincoln Pharmaceuticals Ltd. | 41.11 | 12.21 | 12.27% | 335.34 | ₹645.71 cr |
To understand where Curis Lifesciences stands, above is a comparison with listed pharma companies.
Curis Lifesciences’ RoNW and margins make it competitive, though its revenue scale is much smaller. SME investors often look at future potential rather than size alone, where Curis Lifesciences seems to be positioning itself well.
Promoters and Shareholding Pattern
| Particular | Shares | % Share |
|---|---|---|
| Pre-Issue Promoter Holding | 59,34,434 | 92.68% |
| Post-Issue Promoter Holding | 80,84,434 | 68.03% |
Promoters include:
• Dharmesh Dashrathbhai Patel
• Siddhant Jayantibhai Pawasia
• Piyush Gordhanbhai Antala
• Jaimik Mansukhbhai Patel
A healthy promoter holding after the issue indicates long-term commitment.
Objects of the Issue
| Purpose | Amount (₹ crores) |
|---|---|
| Upgradation of manufacturing facilities | ₹2.44 |
| Construction of storage facility | ₹3.62 |
| Loan repayment | ₹1.86 |
| Product registrations in foreign markets | ₹2.69 |
| Working capital requirements | ₹11.25 |
| General corporate purposes | – |
The company plans to use the IPO proceeds as follows. Most funds are directed toward capacity expansion and working capital, which supports the company’s growth strategy.
Contact Details
Curis Lifesciences Limited
PF-23, GIDC Sanand – II, Industrial Estate, Sanand, Ahmedabad, Gujarat, 382110
Phone: +91 99045 22543
Email: cs@curisls.com
Website: https://curisls.com/
IPO Registrar Details
MUFG Intime India Pvt. Ltd.
Phone: +91-22-4918 6270
Email: curislifesciences.smeipo@in.mpms.mufg.com
Website: https://in.mpms.mufg.com/Initial_Offer/public-issues.html
Curis Lifesciences IPO FAQs
What is Curis Lifesciences IPO?
It is an NSE SME IPO worth ₹27.52 crores with a price band of ₹120 to ₹128 per share.
What is Curis Lifesciences IPO?
It is an NSE SME IPO worth ₹27.52 crores with a price band of ₹120 to ₹128 per share.
What is the lot size?
The minimum bid is 2,000 shares costing ₹2,56,000.
When is the allotment date?
The allotment will be announced on November 12, 2025.
When is the listing date?
Listing is scheduled for November 14, 2025.
How can I apply?
You can apply through ASBA using your bank account or UPI-based applications via stock brokers.
Expert Comment
Curis Lifesciences presents itself as a steady, growth-oriented pharmaceutical company with rising revenues, expanding markets, and an efficient financial structure. The margins, ROE, and RoNW are strong for an SME player, and the company benefits from a modern manufacturing setup with a wide product portfolio.
The higher lot value may limit retail participation, but from a long-term perspective, the financial performance and planned expansion indicate potential for sustained growth. Investors looking for a reasonably valued SME pharma company may consider this issue for long-term holding after their own due diligence.
